At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
18F fluciclovinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy
In Brief
A Phase 2 clinical trial evaluating 18F fluciclovine for Brain Metastases. Completed, enrolled 23 participants across 9 sites.
Detailed Summary
An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Metastases
CountriesUnited States
CollaboratorsPrecision For Medicine
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartAug 2020
Primary CompletionDec 2021
TodayJul 2026
First PostedJun 1, 2020
Enrollment StartAug 31, 2020
Primary CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.1 years ago
Interventions
18F fluciclovinedrug
18F fluciclovine injection, 185 MegaBecquerel (MBq) (5 Millicurie (mCi)) ± 20%, delivered as an intravenous bolus